The Oklahoma Medical Research Foundation , located in Oklahoma City, Oklahoma, is an independent, nonprofit biomedical research institute. Established in 1946, OMRF is dedicated to understanding and developing more effective treatments for human disease. Stephen M. Prescott, M.D., serves as president of OMRF, which employs more than 500 scientific and administrative staff members.OMRF’s scientists, who include a member of the National Academy of Sciences and a Howard Hughes Medical Institute investigator, hold more than 500 U.S. and international patents and have spun off 11 biotech companies. Discoveries at OMRF led to Xigris, the first FDA-approved drug for the treatment of severe sepsis, and Ceprotin, a therapy for people suffering from a rare and life-threatening blood disorder known as protein C deficiency. Research at OMRF also identified the enzyme believed responsible for Alzheimer’s disease and laid the groundwork for OncoVue, a breast cancer risk assessment test. Wikipedia.
Oklahoma Medical Research Foundation | Date: 2015-06-09
The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing these antibodies are described herein as are methods of screening for and detecting these antibodies.
Oklahoma Medical Research Foundation and Johns Hopkins University | Date: 2014-06-26
The present invention relates to a system and a medium for analyzing one or more analytes in rheumatoid arthritis subjects to determine whether the subject is at increased risk of diseases such as a cardiovascular disease, the subjects current cardiovascular disease burden, and the likelihood of cardiovascular disease progression in the subject. In addition, the present invention further provides methods for analyzing data to determine risk of cardiovascular disease, current cardiovascular disease burden, and the likelihood of cardiovascular disease progression in a rheumatoid arthritis subject.
Oklahoma Medical Research Foundation | Date: 2014-10-02
The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.
Oklahoma Medical Research Foundation | Date: 2014-04-08
The present invention provides methods for the prediction and diagnosis of Systemic Lupus Erythematosus using single nucleotide polymorphisms in IRF8.
Oklahoma Medical Research Foundation | Date: 2014-01-21
The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.